Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21

doi:10.3969/j.issn.1673-8640.2023.11.011

Abstract

Abstract:

Objective To investigate the roles of miR-206，miR-125 and miR-21 in efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer. Methods From July 2021 to July 2022，82 breast cancer patients（breast cancer group） who received neo-adjuvant chemotherapy in the First Affiliated Hospital of Hebei North University were enrolled，and 40 healthy subjects were enrolled as healthy control group. The clinical data of all the research subjects were collected，and serum levels of miR-206，miR-125 and miR-21 in breast cancer group before chemotherapy and healthy control group were determined. According to the efficacy of neo-adjuvant chemotherapy，the research subjects were classified into chemotherapy ineffective group and chemotherapy effective group. The patients were followed up for 1 year after chemotherapy，and they were classified into survival group and death group according to the survival of breast cancer patients. Logistic regression analysis was used to evaluate the influencing factors of neo-adjuvant chemotherapy in breast cancer patients. The efficacy of various indicators for evaluating neo-adjuvant chemotherapy was evaluated by receiver operating characteristic（ROC） curve. Kaplan-Meier survival curve was used to evaluate the survival of breast cancer patients. Cox regression analysis was used to evaluate the risk factors affecting the survival rate of breast cancer patients. Results The relative expression levels of miR-206 and miR-125 in serum of breast cancer group were lower than those of healthy control group（P<0.001），and the relative expression level of miR-21 in serum was higher than that of healthy control group（P<0.001）. There was statistical significance in tumor diameter，clinical stage，pathological grade and relative expression levels of miR-206，miR-125 and miR-21 in serum between chemotherapy ineffective group and chemotherapy effective group（P<0.05）. The area under curve（AUC） for single and combined determinations of miR-206，miR-125 and miR-21 to evaluate chemotherapy efficacy were 0.795，0.761，0.782 and 0.899，respectively. Multivariate Logistic regression analysis showed that after adjusting tumor diameter，clinical stage and pathological grade，the low expression of miR-206，miR-125 and high expression of miR-21 in serum were independent risk factors for chemotherapy ineffectiveness in breast cancer patients（P<0.05）. There was statistical significance in clinical stage，pathological grade and relative expression levels of serum miR-206，miR-125 and miR-21 between survival group and death group（P<0.05）. The AUC of serum miR-206，miR-125，miR-21 single and combined determinations to judge the 1-year death of breast cancer patients were 0.757，0.698，0.676，0.838，respectively. Kaplan-Meier survival curve analysis results showed that the 1-year survival rates of miR-206 high expression group and miR-125 high expression group were higher than those of serum miR-206 low expression group and miR-125 low expression group，respectively（P<0.05）. The 1-year survival rates of miR-21 low expression group were higher than those of miR-21 high expression group（P<0.05）. Cox regression analysis showed that after adjusting clinical stage and pathological grade，the low expression of miR-206，miR-125 and high expression of miR-21 in serum were independent risk factors for 1-year death of breast cancer patients（P<0.05）. Conclusions The abnormal expressions of miR-206，miR-125 and miR-21 in serum of patients with breast cancer may be used as the indicators for evaluating efficacy and prognosis of patients receiving neo-adjuvant chemotherapy.

Key words: MicroRNA-206, MicroRNA-125, MicroRNA-21, Breast cancer, Neo-adjuvant chemotherapy

CLC Number:

R446.7

GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21[J]. Laboratory Medicine, 2023, 38(11): 1062-1068.

Figures/Tables 10

References 22

[1]	NAIK A, AL-YAHYAEE A, ABDULLAH N, et al. Neuropilin-1 promotes the oncogenic Tenascin-C/integrin β3 pathway and modulates chemoresistance in breast cancer cells[J]. BMC Cancer, 2018, 18(1):533. DOI PMID
[2]	王文胜, 马志强, 张冠男, 等. MRP1蛋白表达情况与乳腺癌新辅助化疗疗效的关系[J]. 癌症进展, 2018, 16(3):339-341.
[3]	WANG L, ASIRVATHAM J R, MA Y, et al. HER-2/neu-positive breast cancer neoadjuvant chemotherapy response after implementation of 2018 ASCO/CAP focused update[J]. Breast J, 2021, 27(8):631-637. DOI URL
[4]	梁心红, 李玉林, 张冬兰, 等. 乳腺癌新辅助化疗后肿瘤退缩模式对病理完全缓解的预测作用[J]. 中国医学影像学杂志, 2021, 29(4):318-324.
[5]	王瑞鸽, 颜子千, 邓梓坤, 等. MiR-206与ANXA2的3'UTR靶向结合抑制乳腺癌侵袭[J]. 中国生物化学与分子生物学报, 2018, 34(4):434-439. DOI
[6]	KSHRAMAN M, RÖSKE A, LAUFER T, et al. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer[J]. Sci Rep, 2018, 8(1):11584. DOI PMID
[7]	覃舒婷, 莫军扬, 张敏敏, 等. miR-206、miR-155在乳腺癌中的表达及其与激素受体相关性分析[J]. 重庆医学, 2019, 48(19):3380-3383.
[8]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J]. 中国癌症杂志, 2017, 27(9):695-759. DOI
[9]	EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247. DOI URL
[10]	DEDIU M, ZIELINSKI C. A proposal to redefine pathologic complete remission as endpoint following neoadjuvant chemotherapy in early breast cancer[J]. Breast care(Basel), 2021, 15(1):67-71.
[11]	朱雪琳, 伍建林. MRI影像组学预测乳腺癌新辅助化疗疗效及预后研究进展[J]. 磁共振成像, 2022, 13(3):159-161.
[12]	AHMED F, IJAZ B, AHMAD Z, et al. Modification of miRNA expression through plant extracts and compounds against breast cancer:mechanism and translational significance[J]. Phytomedicine, 2020, 68:153168. DOI URL
[13]	杜喜风, 胡志辉, 景敏洁, 等. miR-206过表达对甲状腺乳头状癌细胞增殖和迁移的影响[J]. 中国病理生理杂志, 2020, 36(5):871-876.
[14]	莫军扬, 张敏敏, 唐茜, 等. miRNA-206在乳腺癌中的表达及与内分泌耐药相关性研究[J]. 广西医科大学学报, 2021, 38(3):566-569.
[15]	岳小丁, 李秀娟, 刘青, 等. 白藜芦醇通过诱导细胞周期阻滞及细胞凋亡增强宫颈癌细胞的化疗敏感性[J]. 西安交通大学学报(医学版), 2019, 40(5):736-741.
[16]	齐正, 薛云, 李宗良, 等. miR-6775-3p在乳腺癌细胞中的表达及其对乳腺癌细胞生物学行为的影响[J]. 中国癌症杂志, 2020, 30(12):984-990.
[17]	董建兰, 何英, 孙云菊. MiR-125a-5p在人乳腺癌细胞侵袭和转移中的作用机制研究[J]. 中国妇幼保健, 2022, 37(3):534-537.
[18]	YAN L, YU M, GAO G, et al. MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1[J]. Journal of Cellular Biochemistry, 2018, 119(11):8773-8783. DOI PMID
[19]	骆梅青, 石洁琼, 徐胜源, 等. miR-125a-5p靶向调控HER-2表达抑制乳腺癌细胞生物学活性[J]. 临床肿瘤学杂志, 2019, 24(6):500-505.
[20]	鲁文红, 刘翀, 刘爱林. miR-125b对乳腺癌MCF-7细胞增殖和凋亡的影响[J]. 中国妇幼保健, 2019, 34(17):4073-4076.
[21]	WANG C, PENG R, ZENG M, et al. An autoregulatory feedback loop of miR-21/VMP1 is responsible for the abnormal expression of miR-21 in colorectal cancer cells[J]. Cell Death Dis, 2020, 11(12):1067. DOI PMID
[22]	吴春锋, 夏训和, 沈晓燕, 等. miR-21和miR-218及miR-23a表达水平对新辅助化疗乳腺癌患者预后评价的意义[J]. 中国肿瘤临床与康复, 2021, 28(7):778-781.

组别	例数	miR-206	miR-125	miR-21
乳腺癌组	82	0.72±0.19	0.94±0.25	3.28±0.67
正常对照组	40	1.27±0.31	1.86±0.37	1.05±0.28
t值		12.094	16.203	20.175
P值		<0.001	<0.001	<0.001

组别	例数	miR-206	miR-125	miR-21
乳腺癌组	82	0.72±0.19	0.94±0.25	3.28±0.67
正常对照组	40	1.27±0.31	1.86±0.37	1.05±0.28
t值		12.094	16.203	20.175
P值		<0.001	<0.001	<0.001

组别	例数	年龄		肿瘤数量		肿瘤直径/cm
组别	例数	<50岁/[例（%）]	≥50岁/[例（%）]	单个/[例（%）]	多个/[例（%）]	肿瘤直径/cm
化疗无效组	25	12（48.00）	13（52.00）	17（68.00）	8（32.00）	4.35±1.44
化疗有效组	57	27（47.37）	30（52.63）	42（73.68）	15（26.32）	3.48±1.29
统计值		0.149		0.278		2.713
P值		0.699		0.598		0.008
组别	Ki-67高表达/ [例（%）]	存在月经/ [例（%）]	体重指数/ （kg/m²）	临床分期
组别	Ki-67高表达/ [例（%）]	存在月经/ [例（%）]	体重指数/ （kg/m²）	I期/[例（%）]	Ⅱ期/[例（%）]	Ⅲ期/[例（%）]
化疗无效组	19（76.00）	12（48.00）	23.68±2.57	3（12.00）	12（48.00）	10（40.00）
化疗有效组	35（61.40）	30（52.63）	23.42±2.18	20（35.09）	27（47.37）	10（17.54）
统计值	1.647	0.149	0.470		2.427
P值	0.199	0.699	0.639		0.015
组别	病理分级			miR-206	miR-125	miR-21
组别	高分化/[例（%）]	中分化/[例（%）]	低分化/[例（%）]	miR-206	miR-125	miR-21
化疗无效组	3（12.00）	11（44.00）	11（44.00）	0.59±0.18	0.79±0.23	3.66±0.58
化疗有效组	21（36.84）	26（28.07）	10（17.54）	0.78±0.22	1.01±0.26	3.11±0.65
统计值		2.686		3.793	3.648	3.640
P值		0.007		<0.001	<0.001	<0.001

组别	例数	年龄		肿瘤数量		肿瘤直径/cm
组别	例数	<50岁/[例（%）]	≥50岁/[例（%）]	单个/[例（%）]	多个/[例（%）]	肿瘤直径/cm
化疗无效组	25	12（48.00）	13（52.00）	17（68.00）	8（32.00）	4.35±1.44
化疗有效组	57	27（47.37）	30（52.63）	42（73.68）	15（26.32）	3.48±1.29
统计值		0.149		0.278		2.713
P值		0.699		0.598		0.008
组别	Ki-67高表达/ [例（%）]	存在月经/ [例（%）]	体重指数/ （kg/m²）	临床分期
组别	Ki-67高表达/ [例（%）]	存在月经/ [例（%）]	体重指数/ （kg/m²）	I期/[例（%）]	Ⅱ期/[例（%）]	Ⅲ期/[例（%）]
化疗无效组	19（76.00）	12（48.00）	23.68±2.57	3（12.00）	12（48.00）	10（40.00）
化疗有效组	35（61.40）	30（52.63）	23.42±2.18	20（35.09）	27（47.37）	10（17.54）
统计值	1.647	0.149	0.470		2.427
P值	0.199	0.699	0.639		0.015
组别	病理分级			miR-206	miR-125	miR-21
组别	高分化/[例（%）]	中分化/[例（%）]	低分化/[例（%）]	miR-206	miR-125	miR-21
化疗无效组	3（12.00）	11（44.00）	11（44.00）	0.59±0.18	0.79±0.23	3.66±0.58
化疗有效组	21（36.84）	26（28.07）	10（17.54）	0.78±0.22	1.01±0.26	3.11±0.65
统计值		2.686		3.793	3.648	3.640
P值		0.007		<0.001	<0.001	<0.001

项目	β值	标准误	Wald值	P值	OR值（95%CI）
miR-206	-0.826	0.263	9.866	<0.001	0.438（0.232~0.826）
miR-125	-0.840	0.241	12.152	<0.001	0.432（0.257~0.725）
miR-21	1.507	0.509	8.763	<0.001	4.512（2.886~7.054）